Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025
Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025
forte biosciences成功融資5300萬美元，定向增發已超額認購，以推動FB102臨床項目在自身免疫適應症領域的進展，預計2025年公佈關鍵數據。
Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025
forte biosciences在超額認購的定向增發中獲得5300萬美元，以推進FB102在自身免疫疾病領域的臨床項目，預計將於2025年發佈關鍵數據。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間